Introduction to Pregnancy in Primary Pulmonary Hypertension (PPH)

Primary Pulmonary Hypertension (PPH) associated with pregnancy carries a high maternal mortality rate. Short-term epoprostenol infusion has been demonstrated to improve the hemodynamic profile in patients with Primary Pulmonary Hypertension (PPH). We report a successful maternal-fetal outcome with epoprostenol therapy during pregnancy, cesarean section, and postpartum in a patient with Primary Pulmonary Hypertension (PPH). Epoprostenol therapy did not produce any physical or developmental abnormalities in the fetus. A favorable maternal-fetal outcome may occur with a multidisciplinary approach.

Primary Pulmonary Hypertension (PPH) is a rare, progressive condition aggravated by the physiologic changes occurring during pregnancy and surgery. The maternal mortality rate associated with pregnancy and pulmonary hypertension ranges from 30 to 50%. The administration of IV epoprostenol has been well-demonstrated to improve hemodynamics in nonpregnant patients with PPHPrimary Pulmonary Hypertension (PPH) We report a successful maternal-fetal outcome in a pregnant woman in whom Primary Pulmonary Hypertension (PPH) was diagnosed who was treated with IV epoprostenol before, during, and after undergoing cesarean section.